Your browser doesn't support javascript.
loading
Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives.
de Fougerolles, Thierry Rigoine; Baïssas, Théophile; Perquier, Guillaume; Vitoux, Olivier; Crépey, Pascal; Bartelt-Hofer, José; Bricout, Hélène; Petitjean, Audrey.
Afiliación
  • de Fougerolles TR; Corporate Value Associates, Paris, France.
  • Baïssas T; Corporate Value Associates, London, UK.
  • Perquier G; Corporate Value Associates, Paris, France.
  • Vitoux O; Corporate Value Associates, Paris, France.
  • Crépey P; Univ Rennes, EHESP, CNRS, INSERM, Arènes - UMR 6051, RSMS - U 1309, Rennes, France.
  • Bartelt-Hofer J; Sanofi, 14, Espace Henry Vallée, 69007, Lyon, France. jose.bartelt-hofer@sanofi.com.
  • Bricout H; Sanofi, 14, Espace Henry Vallée, 69007, Lyon, France.
  • Petitjean A; Sanofi, 14, Espace Henry Vallée, 69007, Lyon, France.
BMC Public Health ; 24(1): 1222, 2024 May 03.
Article en En | MEDLINE | ID: mdl-38702667
ABSTRACT

BACKGROUND:

Seasonal influenza epidemics have a substantial public health and economic burden, which can be alleviated through vaccination. The World Health Organization (WHO) recommends a 75% vaccination coverage rate (VCR) in older adults (aged ≥ 65 years), individuals with chronic conditions, pregnant women, children aged 6-24 months and healthcare workers. However, no European country achieves this target in all risk groups. In this study, potential public health and economic benefits achieved by reaching 75% influenza VCR was estimated in risk groups across four European countries France, Italy, Spain, and the UK.

METHODS:

A static epidemiological model was used to estimate the averted public health and economic burden of increasing the 2021/2022 season VCR to 75%, using the efficacy data of standard-dose quadrivalent influenza vaccine. For each country and risk group, the most recent data on population size, VCR, pre-pandemic influenza epidemiology, direct medical costs and absenteeism were identified through a systematic literature review, supplemented by manual searching. Outcomes were averted influenza cases, general practitioner (GP) visits, hospitalisations, case fatalities, number of days of work lost, direct medical costs and absenteeism-related costs.

RESULTS:

As of the 2021/2022 season, the UK achieved the highest weighted VCR across risk groups (65%), followed by Spain (47%), France (44%) and Italy (44%). Based on modelling, the 2021/2022 VCR prevented an estimated 1.9 million influenza cases, avoiding 375,200 GP visits, 73,200 hospitalisations and 38,400 deaths. To achieve the WHO 75% VCR target, an additional 24 million at-risk individuals would need to be vaccinated, most of which being older adults and patients with chronic conditions. It was estimated that this could avoid a further 918,200 influenza cases, 332,000 GP visits, 16,300 hospitalisations and 6,300 deaths across the four countries, with older adults accounting for 52% of hospitalisations and 80% of deaths. An additional €84 million in direct medical costs and €79 million in absenteeism costs would be saved in total, with most economic benefits delivered in France.

CONCLUSIONS:

Older adults represent most vaccine-preventable influenza cases and deaths, followed by individuals with chronic conditions. Health authorities should prioritise vaccinating these populations for maximum public health and economic benefits.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Salud Pública / Gripe Humana País/Región como asunto: Europa Idioma: En Revista: BMC Public Health Asunto de la revista: SAUDE PUBLICA Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Salud Pública / Gripe Humana País/Región como asunto: Europa Idioma: En Revista: BMC Public Health Asunto de la revista: SAUDE PUBLICA Año: 2024 Tipo del documento: Article